6 results on '"Askold Kucher"'
Search Results
2. Medical Database and Decision System for the Analysis of the Thyroid Pathologies
- Author
-
Anton Vovk, Andriy Fechan, Mikola Kushnirchuk, Oksana Boyko, Askold Kucher, and Oleksiy Dutchak
- Published
- 2021
3. Decision Support System for the Diagnosis of Thyroid Cancer
- Author
-
Oksana Boyko, Askold Kucher, Olesia Chaban, Ihor Ogirko, Volodymyr Yuzevych, and Oleksiy Dutchak
- Subjects
Protocol (science) ,Thyroid nodules ,medicine.medical_specialty ,Decision support system ,Artificial neural network ,Computer science ,Thyroid ,Retrospective cohort study ,medicine.disease ,medicine.anatomical_structure ,Aspiration biopsy ,medicine ,Medical physics ,Thyroid cancer - Abstract
A retrospective study of the results of the examination of 220 patients who underwent fine-needle aspiration biopsy of thyroid nodules has been conducted. Possibilities of using the TI-RADS (Thyroid Imaging Reporting and Data System) scale as a standardized ultrasonographic thyroid examination protocol have been considered. A new approach for determining the relationship between the results of ultrasonographic examination and cytological examination of the thyroid nodules based on computer simulations has been proposed. Using the approaches of the global optimization criterion, neural networks and TI-RADS systems, a diagram of the thyroid cancer diagnosing process in BPWin Process Modeller has been created. We have also developed a methodology for estimating the uncertainty of experimental studies. Based on the research results, a structural scheme of the decision support system was developed to model the procedure for the diagnosis of thyroid cancer and the principles of functioning of the corresponding information processing technology, taking into account quality criteria, risk theory and artificial neural network techniques.
- Published
- 2021
4. MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma
- Author
-
Robert Prosecky, Lesia Tumanovska, Peter Urdzík, D. O. Stroy, Yuriy Borys, Victor E. Dosenko, Yulian Mytsyk, Luis Rodrigo, Askold Kucher, Katarina Gazdikova, and Peter Kruzliak
- Subjects
0301 basic medicine ,Oncology ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Kidney ,Nephrectomy ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Carcinoma, Renal Cell ,Survival analysis ,Retrospective Studies ,business.industry ,Cancer ,General Medicine ,medicine.disease ,Prognosis ,Survival Analysis ,Kidney Neoplasms ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,Clear cell renal cell carcinoma ,MicroRNAs ,030104 developmental biology ,Real-time polymerase chain reaction ,Treatment Outcome ,030220 oncology & carcinogenesis ,Lymphatic Metastasis ,Biomarker (medicine) ,Female ,business ,Clear cell - Abstract
None of the currently investigated molecular markers demonstrated sufficient accuracy in prognostication of the renal cell carcinoma (RCC) oncologic outcomes; thus, none of them has been recommended for the application in the routine clinical practice. The role of miR-15a as a potential prognostic marker for RCC is still not unveiled. The aim of our study was to assess the expression of miR-15a in tumor tissues of the patients with RCC and to evaluate the possibility of its usage as a prognostic molecular biomarker of this disease. The retrospective included 64 adult patients with clear cell RCC (ccRCC) in whom radical or partial nephrectomy was conducted. After deparaffinization of formalin-fixed paraffin-embedded (FFPE) ccRCC specimens, the tissue expression of miR-15a was measured using the reverse transcription and quantitative polymerase chain reaction in the real time. For the reference, the expression of miR-15a was estimated in 15 FFPE tissue specimens of the normal renal parenchyma. Survival analysis involved all cases of non-metastatic RCCs (n = 57). Five-year cancer-specific survival (CSS) was estimated by means of the Kaplan–Meier method and was calculated from the date of surgery to the date of death. Patients with the RCC were characterized by significantly upregulated tumor tissue mean levels of miR-15a compared to the healthy controls: 0.10 ± 2.62 relative units (RU) versus 4.84E − 03 ± 3.11E − 03 RU (p
- Published
- 2019
5. MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma
- Author
-
Askold Kucher, Peter Kruzliak, Manyuk Lubov, Yulian Mytsyk, Katarina Gazdikova, Ammad Ahmad Farooqi, Victor E. Dosenko, Yuriy Borys, Martin Caprnda, and Dietrich Büsselberg
- Subjects
0301 basic medicine ,Nephrology ,Adenoma ,Male ,medicine.medical_specialty ,Angiomyolipoma ,Urology ,medicine.medical_treatment ,Chromophobe cell ,urologic and male genital diseases ,Nephrectomy ,Polymerase Chain Reaction ,Sensitivity and Specificity ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,Internal medicine ,medicine ,Biomarkers, Tumor ,Adenoma, Oxyphilic ,Humans ,Oncocytoma ,Carcinoma, Renal Cell ,Aged ,Neoplasm Staging ,business.industry ,Papillary Adenoma ,Middle Aged ,medicine.disease ,female genital diseases and pregnancy complications ,Kidney Neoplasms ,Tumor Burden ,MicroRNAs ,030104 developmental biology ,030220 oncology & carcinogenesis ,Case-Control Studies ,Biomarker (medicine) ,Female ,business - Abstract
Currently, there is no accurate diagnostic molecular biomarker for renal cell carcinoma (RCC). The aim of this study was to assess the expression of microRNA-15a (miR-15a) in urine of patients with RCC and to evaluate its potential as a diagnostic molecular biomarker.In total, 67 patients with solid renal tumors were enrolled: clear-cell RCC (ccRCC, n = 22), papillary RCC (pRCC, n = 16), chromophobe RCC (chRCC, n = 14), oncocytoma (n = 8), papillary adenoma (n = 2) and angiomyolipoma (n = 5). MiRNA-15a expression levels measurement in urine were performed using qPCR. Urine of 15 healthy volunteers without kidney pathology was used as control.We observed a difference in mean miR-15a expression values in groups of pre-operative patients with RCC, benign renal tumors and healthy persons (2.50E-01 ± 2.72E-01 vs 1.32E-03 ± 3.90E-03 vs 3.36E-07 ± 1.04E-07 RFU, respectively, p 0.01). There was no difference in miR-15a expression between ccRCC, pRCC and chRCC (p 0.05). Direct association between RCC size and miR-15a expression values was obtained (Pearson correlation coefficient-0.873). On the 8th day after nephrectomy, mean expression value in patients with RCC decreased by 99.53% (p 0.01). MiR-15a expression differentiated RCC from benign renal tumors with 98.1% specificity, 100% sensitivity at a cut-off value of 5.00E-06 RFU, with AUC-0.955.MiR-15a expression measured in urine may be used as diagnostic molecular biomarker for RCC.
- Published
- 2018
6. Potential clinical applications of microRNAs as biomarkers of renal cell carcinoma
- Author
-
Victor E. Dosenko, Yuriy Borys, Vasyl Kowalskyy, Serhyi Pasichnyk, Oleh Mytsyk, Yulian Mytsyk, Yuriy Diychuk, Michał A. Skrzypczyk, Askold Kucher, and Lubov Manyuk
- Subjects
0301 basic medicine ,renal cell carcinoma ,medicine.medical_treatment ,Disease ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,microRNA ,diagnostics ,medicine ,Pathological ,Review Paper ,Kidney ,Cell growth ,business.industry ,prediction ,General Medicine ,medicine.disease ,Nephrectomy ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cancer research ,biomarker ,Biomarker (medicine) ,prognosis ,business - Abstract
Introduction Renal cell carcinoma (RCC) accounts for 3% of adult malignancies and more than 90% of kidney neoplasms. High rates of undiagnostic percutaneous kidney biopsies and difficulties in reliable pre-operative differentiation between malignant and benign renal tumors using contemporary imaging techniques result in large numbers of redundant surgeries. Absence of specific biomarkers for early detection and monitoring complicates on-time diagnosis of the disease and relapse. For the patients followed up after having a nephrectomy, a noninvasive and sensitive biomarker enabling early detection of disease relapse would be extremely useful. Material and methods The study is a review of recent knowledge regarding potential clinical applications of microRNAs (miRNAs) as biomarkers of RCC. Results MicroRNAs are essential regulators of various processes such as cell proliferation, differentiation, development and death; they have been implicated in diverse biological and pathological processes in RCC. There is a class of miRNAs that promote RCC development (oncomirs) and a class of miRNAs that negatively regulate oncogenes, suppress tumor growth and invasion, and thus could be considered treatment agents (anti-oncomirs). Separate miRNAs and specific miRNAs expression profiles have been identified, enabling early detection of the disease, prediction of response to systemic therapy, or prognostication of biological behavior of the disease. Conclusions The miRNA network analysis and gene profiling may help to identify the most sensible molecular signatures of RCC that can be used for diagnostic purposes, as well as poor prognosis signatures and poor therapeutic response signatures in patients who undergo systemic therapy.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.